These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7873482)

  • 41. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
    J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer.
    Yano M; Shiozaki H; Inoue M; Tamura S; Doki Y; Yasuda T; Fujiwara Y; Tsujinaka T; Monden M
    World J Surg; 2002 Sep; 26(9):1155-9. PubMed ID: 12209246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
    Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
    Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case of lymph node recurrence of endocrine cell carcinoma of stomach effectively treated with carboplatin and etoposide].
    Ohashi N; Jinno S; Shimokata T; Kobayashi D; Tanaka C; Fujiwara M; Yamada S; Fujii T; Nomoto S; Takeda S; Kodera Y
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2545-8. PubMed ID: 23235176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
    Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
    J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
    Yamashita K; Ushiku H; Katada N; Hosoda K; Moriya H; Mieno H; Kikuchi S; Hoshi K; Watanabe M
    Eur J Surg Oncol; 2015 Oct; 41(10):1324-32. PubMed ID: 26251341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgical and combined treatment of gastric cancer--own experience.
    Berner J; Tenderenda M; Pasz S; Berner A; Piekarski J
    Przegl Lek; 2000; 57 Suppl 5():14-5. PubMed ID: 11202279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer.
    Chipponi J; Huguier M; Pezet D; Basso N; Hay JM; Quandalle P; Jaeck D; Fagniez PL; Gainant A
    Am J Surg; 2004 Mar; 187(3):440-5. PubMed ID: 15006580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer.
    Petrioli R; Sabatino M; Roviello F; Marrelli D; Nastri G; Marsili S; Correale P; Pozzessere D; Messinese S; De Martino A; Tani F; Marzocca G; Lorenzi M; Civitelli S; Tanzini G; Pinto E; Francini G
    Hepatogastroenterology; 2005; 52(65):1626-30. PubMed ID: 16201130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Stiekema J; Trip AK; Jansen EP; Boot H; Cats A; Ponz OB; Verheij M; van Sandick JW
    Ann Surg Oncol; 2014 Apr; 21(4):1107-14. PubMed ID: 24306660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
    Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study.
    Frasci G; Tortoriello A; Facchini G; Conforti S; Persico G; Mastrantonio P; Cardone A; Iaffaioli RV
    Eur J Cancer; 1994; 30A(7):946-50. PubMed ID: 7946589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mobilization of peripheral blood stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in advanced gastric cancer.
    Ueda Y; Sonoda Y; Fujiki H; Harada S; Kimura T; Itoh T; Imura K; Naito K; Nomura K; Taniwaki M; Yamagishi H
    Oncol Rep; 2004 Aug; 12(2):323-32. PubMed ID: 15254697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
    Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
    J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraperitoneal perfusion chemotherapy and whole abdominal hyperthermia using external radiofrequency following radical D2 resection for treatment of advanced gastric cancer.
    Zhu L; Xu Y; Shan Y; Zheng R; Wu Z; Ma S
    Int J Hyperthermia; 2019; 36(1):403-407. PubMed ID: 30829551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Kim SM; An JY; Lee J; Sohn TS; Kim S
    Ann Surg Oncol; 2018 Jun; 25(6):1616-1624. PubMed ID: 29569127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.